S
Silver Creek Pharmaceuticals
Developing a pipeline of innovative new regenerative medicines to treat a range of serious diseases
About Silver Creek Pharmaceuticals
Silver Creek Pharmaceuticals is a research and development-focused company specializing in innovative treatments for acute injuries to well-perfused organs such as the heart, kidney, and brain. The company leverages computational modeling to discover protein engineering design principles that drive apoptosis, or programmed cell death. Silver Creek's competitive advantages include a strong global network through its board of directors, cost-effective in-house studies, and support from Key Opinion Leaders (KOLs). The company aims to bring its drugs through clinical trials and into the market by forming partnerships with global pharmaceutical companies. Silver Creek's primary focus is on developing a Smart Growth Factor (SGF) to aid patients suffering from organ damage due to ischemic events, including acute kidney, heart, and brain injuries. The company operates in the biopharmaceutical market, targeting conditions with high unmet medical needs. Its business model involves early-stage drug development, followed by strategic partnerships for commercialization. Revenue is generated through licensing agreements and milestone payments from partner pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 37.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Innovation Management, Biotechnology, Cardiology and cardiovascular, Tissue Engineering, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCEquity / VC | Feb 2022 | $9.2M | $37M | Undisclosed | — |
| EARLY VC✓Equity / VC | Feb 2018 | $20M | $80M | Goldman Sachs · JP Morgan | — |
Growth signals
Latest recorded traffic for Silver Creek Pharmaceuticals is 900 monthly website visits, down 62.5% over the last three months. Silver Creek Pharmaceuticals's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Silver Creek Pharmaceuticals in the South San Francisco ecosystem
The Silver Creek Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Silver Creek Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Silver Creek Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.












